Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy

Study identifier:LB-001LT

ClinicalTrials.gov identifier:NCT05506254

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Long-term Follow-up Study of Patients in LogicBio Clinical Trials for Methylmalonic Acidemia Characterized by MMUT Mutations Who Received hLB-001

Medical condition

Methylmalonic Acidemia

Phase

Healthy volunteers

Study drug

hLB-001

Sex

All

Actual Enrollment

Study type

Observational

Age

N/A

Date

Study Start Date: 20 Jul 2022

Estimated Primary Completion Date: 31 Dec 2037

Estimated Study Completion Date: 31 Dec 2037

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Dec 2024 by LogicBio Therapeutics, Inc.

Collaborators

Alexion Pharmaceuticals, Inc.

Inclusion and exclusion criteria

Location

Clinical Trial Site

Nashville, Tennessee, United States, 37232

Location

Clinical Trial Site

Seattle, Washington, United States, 98105

Location

Clinical Trial Site

Atlanta, Georgia, United States, 30322

Location

Clinical Trial Site

Pittsburg, Pennsylvania, United States, 15224

Arms	Assigned Interventions
Patients who have previously received hLB-001	-

Contacts

Contact

Alexion Pharmaceuticals, Inc.

1-855-752-2356

clinicaltrials@alexion.com

Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Clinical Trial Site

Clinical Trial Site

Clinical Trial Site

Clinical Trial Site

Contacts

Contact